Histone Deacetylase Inhibitors in Cancer Therapy

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Biology

Background:

• Histone deacetylases (HDACs) are epigenetic modifiers regulating gene transcription.
• Aberrant HDACs expression, mutation, or recruitment is implicated in various cancers.
• HDACs play a role in tumorigenesis via multiple biological pathways.

Purpose of the Study:

• To review the functional mechanisms of HDAC inhibitors.
• To discuss the anti-tumor effects of HDAC inhibitors.
• To explore potential clinical applications and synergistic effects of HDAC inhibitors in combination therapy.

Main Methods:

• Literature review of HDAC inhibitors.
• Analysis of functional mechanisms.
• Evaluation of clinical applications and combination strategies.

Main Results:

• HDAC inhibitors exert anti-tumor effects through specific functional mechanisms.
• HDAC inhibitors demonstrate potential in clinical settings.
• Combinational treatments involving HDAC inhibitors may enhance therapeutic efficacy.

Conclusions:

• HDACs are significant targets for cancer therapy.
• HDAC inhibitors represent a promising class of anti-cancer drugs.
• Further research into clinical applications and combination therapies is warranted.